0001562180-23-001082.txt : 20230207 0001562180-23-001082.hdr.sgml : 20230207 20230207161112 ACCESSION NUMBER: 0001562180-23-001082 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230203 FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Robichaud Albert CENTRAL INDEX KEY: 0001612861 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36544 FILM NUMBER: 23595186 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sage Therapeutics, Inc. CENTRAL INDEX KEY: 0001597553 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-299-8380 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2023-02-03 false 0001597553 Sage Therapeutics, Inc. SAGE 0001612861 Robichaud Albert C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET CAMBRIDGE MA 02142 false true false false Chief Scientific Officer Common Stock 2023-02-03 4 A false 3375.00 0.00 A 146680.00 D Common Stock 2023-02-03 4 F false 1127.00 44.16 D 145553.00 D On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 11,250 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 3,375 shares. Reflects beneficial ownership balance which includes 279 shares purchased on June 30, 2022 and 397 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan. /s/ Anne Marie Cook, as Attorney-in-Fact for Albert Robichaud 2023-02-07 EX-24 2 alrobichaudpoa2019.txt AL ROBICHAUD POA 2019 POWER OF ATTORNEY I, the undersigned, hereby authorize and designate Anne Marie Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer), Erin Lanciani (SVP, People and Organizational Strategy), and Jennifer Fitzpatrick (Vice President, Corporate Counsel) for as long as they remain employees of Sage Therapeutics, Inc., and Laurie Burlingame of Goodwin Procter, each acting singly, or their successors in role, to take the following actions, acting as my agent and attorney-in-fact, with full power of substitution: (1) to prepare and sign on my behalf any Form 3, Form 4 or Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, and to file the same with the Securities and Exchange Commission, NASDAQ, NYSE, and each stock exchange on which shares of Common Stock or other securities of Sage Therapeutics, Inc. are listed, as required by law; (2) to prepare and sign on my behalf any Form 144 pursuant to the Securities Act of 1933, as amended, and to file the same with the Securities and Exchange Commission, NASDAQ, NYSE, and each stock exchange on which shares of Common Stock or other securities of Sage Therapeutics, Inc. are listed, as required by law; and (3) take any other action necessary or proper in connection with the foregoing. Unless earlier revoked under the next sentence, this Power of Attorney shall remain in effect as long as I am an executive officer or director of Sage Therapeutics, Inc., and shall not be affected by my subsequent disability or incompetence. I may revoke this Power of Attorney by written notice delivered, in person or by nationally recognized courier, to the attention of the SVP, General Counsel of Sage Therapeutics, Inc. /s/ Albert J Robichaud ___________________________________________________ (Signature of Executive Officer or Director) Name: Albert J Robichaud Date: 1/03/2019